Sun Pharmaceutical Industries Ltd has appointed Satyavati Berera, former Chief Operating Officer of PwC India, as an Independent Director on its board for a term of five consecutive years, subject to shareholders’ approval through postal ballot.

The company disclosed the development in a National Stock Exchange filing on April 4, 2026. 

According to the filing, the appointment was approved by the Board through a resolution passed on Saturday following the recommendation of the Nomination and Remuneration Committee. Her tenure will become effective from the date shareholders approve the proposal. 

Sun Pharma said the induction of Berera will further strengthen the board’s independence, governance effectiveness and oversight depth, while ensuring continued compliance with the Companies Act, 2013 and SEBI’s listing regulations relating to board composition. 

Berera brings over four decades of leadership experience across assurance, consulting, governance, risk and compliance services. She retired from PwC India in 2023 after serving in multiple senior leadership roles, including COO since 2016. Prior to that, she headed the consulting practice and also served as Managing Partner for PwC’s northern region. 

An economics graduate from Lady Shri Ram College, Delhi University, and a fellow member of the Institute of Chartered Accountants of India, Berera qualified as a Chartered Accountant in 1984 and became a Partner at Price Waterhouse in 1995. Her experience spans finance, operations, human capital, technology, risk, and regulatory compliance. 

The company also clarified that Berera is not related to any director, key managerial personnel or promoter of Sun Pharma and is not debarred from holding the office of director by SEBI or any other authority.